Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
Francesco Bandello1, Umberto De Benedetto1, Karl Anders Knutsson1, Maurizio Battaglia Parodi1, Maria Lucia Cascavilla1, Pierluigi Iacono21Department of Ophthalmology, University Vita-salute, Scientific Institute San Raffaele, Milan, Italy; 2Fondazione G B Bietti per l’Oftalmologia, IRC...
Guardado en:
Autores principales: | Bandello F, De Benedetto U, Knutsson KA, Battaglia Parodi M, Cascavilla ML, Iacono P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/873eb95a24d949748b2783f8ffcf9694 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema
por: Kodjikian L, et al.
Publicado: (2021) -
Critical appraisal of ranibizumab in the treatment of diabetic macular edema
por: Stewart MW
Publicado: (2013) -
Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim M, et al.
Publicado: (2013) -
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim LS, et al.
Publicado: (2015) -
Dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Dugel PU, et al.
Publicado: (2015)